Immuno-Oncology: Taking Immunotherapies to the Next Level

10:30 AM - 12:00 PM, Thursday, June 6,2019 ・ 105AB, Level 100
We have seen great strides in the approval of cancer immunotherapies, treatments that harness the powers of the immune system to battle cancer. Although recent breakthroughs in cancer immunotherapy have deepened our understanding of the mechanisms and pathways that regulate the immune's system response to cancer, the leading agents, the checkpoint inhibitors (CPIs), while demonstrating dramatic effects in certain cancers and patients, in other settings have shown only modest if not negligible clinical benefit. Hence there remains a high unmet need for additional therapies, in particular to be used in combination with CPIs to enhance activity, especially to reverse innate or acquired resistance. This panel will discuss the future of immuno-oncology and combination strategies, new generation of checkpoint inhibitors and novel mechanisms of action for immune engagement.
Speakers
photo
Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center,
photo
President
Precigen Therapeutics
photo
Chief Operating Officer
Agenus, Inc.
photo
Senior Biotechnology Analyst
Bloomberg Intelligence
photo
Associate Vice President
Merck & Co., Inc.
photo
Principal
New Enterprise Associates (NEA)